NMNicole Merten

Nicole Merten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nicole Merten has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Fluorescent Probe Enables the Discovery of Improved Antagonists Targeting the Intracellular Allosteric Site of the Chemokine Receptor CCR7

    by Silas L. Wurnig, Max E. Huber, Corinna Weiler, Hanna Baltrukevich, Nicole Merten, Isabel Stötzel, Teresa Steffen, Yinshui Chang, René H. L. Klammer, Dirk Baumjohann, et al.

    Intracellular ligands of G protein-coupled receptors (GPCRs) are gaining significant interest in drug discovery. Here, we report the development of the fluorescent ligand Mz437 (4) targeting the CC chemokine receptor CCR7 at an intracellular allosteric site. We demonstrate its experimental power by applying 4 to identify two improved intracellular CCR7 antagonists, SLW131 (10) and SLW132 (21m), developed by converting two weakly active antagonists into single- or double-digit nanomolar ligands with minimal modifications. The thiadiazoledioxide 10 was derived from the CCR7 antagonist Cmp2105 by removing a methyl group from the benzamide moiety, while the squaramide 21m was obtained from the CXCR1/CXCR2 antagonist and clinical candidate navarixin by replacing the ethyl substituent by a tert-butyl group to engage a lipophilic subpocket. We show that 10 and 21m qualify to probe CCR7 biology in recombinant and primary immune cells and expect our novel probes to facilitate the design of next-generation intracellular CCR7 ligands.


  • Discovery of Anthranilic Acid Derivatives as Antagonists of the Pro-Inflammatory Orphan G Protein-Coupled Receptor GPR17

    by Nader M. Boshta, Michael Lewash, Meryem Köse, Vigneshwaran Namasivayam, Soumya Sarkar, Jan H. Voss, Andy J. Liedtke, Anna Junker, Maoqun Tian, Anne Stößel, et al.

    The G protein-coupled receptor 17 (GPR17) is an orphan receptor involved in inflammatory diseases. GPR17 antagonists have been proposed for the treatment of multiple sclerosis due to their potential to induce remyelination. Potent, selective antagonists are required to enable target validation. In the present study, we describe the discovery of a novel class of GPR17 antagonists based on an anthranilic acid scaffold. The compounds' potencies were evaluated in calcium mobilization and radioligand binding assays, and structure-activity relationships were analyzed. Selected antagonists were additionally studied in cAMP and G protein activation assays. The most potent antagonists were 5-methoxy-2-(5-(3'-methoxy-[1,1'-biphenyl]-2-yl)furan-2-carboxamido)benzoic acid (52, PSB-22269, Ki 8.91 nM) and its 3'-trifluoromethyl analog (54, PSB-24040, Ki 83.2 nM). Receptor-ligand docking studies revealed that the compounds' binding site is characterized by positively charged arginine residues and a lipophilic pocket. These findings yield valuable insights into this poorly characterized receptor providing a basis for future drug development.


  • Open Access

    Fluorescent Ligands Enable Target Engagement Studies for the Intracellular Allosteric Binding Site of the Chemokine Receptor CXCR2

    by Max E. Huber, Silas Wurnig, Lara Toy, Corinna Weiler, Nicole Merten, Evi Kostenis, Finn K. Hansen, Matthias Schiedel

    Herein, we report the structure-based development of fluorescent ligands targeting the intracellular allosteric binding site (IABS) of CXC chemokine receptor 2 (CXCR2), a G protein-coupled receptor (GPCR) that has been pursued as a drug target in oncology and inflammation. Starting from the cocrystallized intracellular CXCR2 antagonist 00767013 (1), tetramethylrhodamine (TAMRA)-labeled CXCR2 ligands were designed, synthesized, and tested for their suitability as fluorescent reporters to probe binding to the IABS of CXCR2. By means of these studies, we developed Mz438 (9a) as a high-affinity and selective fluorescent CXCR2 ligand, enabling cell-free as well as cellular NanoBRET-based binding studies in a nonisotopic and high-throughput manner. Further, we show that 9a can be used as a tool to visualize intracellular target engagement for CXCR2 via fluorescence microscopy. Thus, our small-molecule-based fluorescent CXCR2 ligand 9a represents a promising tool for future studies of CXCR2 pharmacology.


  • Open Access

    How Carvedilol activates β2-adrenoceptors

    by Tobias Benkel, Mirjam Zimmermann, Julian Zeiner, Sergi Bravo, Nicole Merten, Victor Jun Yu Lim, Edda Sofie Fabienne Matthees, Julia Drube, Elke Miess-Tanneberg, Daniela Malan, et al.

    Carvedilol is among the most effective β-blockers for improving survival after myocardial infarction. Yet the mechanisms by which carvedilol achieves this superior clinical profile are still unclear. Beyond blockade of β1-adrenoceptors, arrestin-biased signalling via β2-adrenoceptors is a molecular mechanism proposed to explain the survival benefits. Here, we offer an alternative mechanism to rationalize carvedilol’s cellular signalling. Using primary and immortalized cells genome-edited by CRISPR/Cas9 to lack either G proteins or arrestins; and combining biological, biochemical, and signalling assays with molecular dynamics simulations, we demonstrate that G proteins drive all detectable carvedilol signalling through β2ARs. Because a clear understanding of how drugs act is imperative to data interpretation in basic and clinical research, to the stratification of clinical trials or to the monitoring of drug effects on the target pathway, the mechanistic insight gained here provides a foundation for the rational development of signalling prototypes that target the β-adrenoceptor system.


  • Open Access

    A Chemical Biology Toolbox Targeting the Intracellular Binding Site of CCR9: Fluorescent Ligands, New Drug Leads and PROTACs

    by Max Erhard Huber, Lara Toy, Maximilian Franz Schmidt, Hannah Vogt, Julian Budzinski, Martin Ferdinand Josef Wiefhoff, Nicole Merten, Evi Kostenis, Dorothee Weikert, Matthias Schiedel

    A conserved intracellular allosteric binding site (IABS) has recently been identified at several G protein‐coupled receptors (GPCRs). Starting from vercirnon, an intracellular C−C chemokine receptor type 9 (CCR9) antagonist and previous phase III clinical candidate for the treatment of Crohn's disease, we developed a chemical biology toolbox targeting the IABS of CCR9. We first synthesized a fluorescent ligand enabling equilibrium and kinetic binding studies via NanoBRET as well as fluorescence microscopy. Applying this molecular tool in a membrane‐based setup and in living cells, we discovered a 4‐aminopyrimidine analogue as a new intracellular CCR9 antagonist with improved affinity. To chemically induce CCR9 degradation, we then developed the first PROTAC targeting the IABS of GPCRs. In a proof‐of‐principle study, we succeeded in showing that our CCR9‐PROTAC is able to reduce CCR9 levels, thereby offering an unprecedented approach to modulate GPCR activity.


  • Open Access

    Chemisch‐biologischer Werkzeugkasten für die intrazelluläre Bindungsstelle von CCR9: Fluoreszierende Liganden, neue Leitstrukturen und PROTACs

    by Max Erhard Huber, Lara Toy, Maximilian Franz Schmidt, Hannah Vogt, Julian Budzinski, Martin Ferdinand Josef Wiefhoff, Nicole Merten, Evi Kostenis, Dorothee Weikert, Matthias Schiedel

    Eine konservierte intrazelluläre allosterische Bindungsstelle (IABS) wurde kürzlich an mehreren G‐Protein‐gekoppelten Rezeptoren (GPCRs) identifiziert. Ausgehend von Vercirnon, einem intrazellulären Antagonisten am C−C‐Chemokin‐Rezeptor‐Typ‐9 (CCR9), entwickelten wir molekulare Werkzeuge, die an der IABS von CCR9 angreifen. Zunächst synthetisierten wir fluoreszierende CCR9‐Liganden, die Bindungsstudien via NanoBRET sowie Fluoreszenzmikroskopie ermöglichten. Deren Anwendung in zellfreien sowie zellulären Testsystemen erlaubte die Identifizierung eines 4‐Aminopyrimidin‐Analogons als neuen intrazellulären CCR9‐Antagonisten mit verbesserter Affinität. Um den proteasomalen Abbau von CCR9 einzuleiten, entwickelten wir das erste PROTAC, das die IABS von GPCRs als Angriffsort nutzt. In einer Machbarkeitsstudie zeigen wir, dass unser CCR9‐PROTAC in der Lage ist, die CCR9‐Spiegel zu reduzieren, was einen konzeptionell neuartigen Ansatz zur Modulation der GPCR‐Aktivität darstellt.

  • Open Access

    Author Correction: Chemokine receptor trafficking coordinates neutrophil clustering and dispersal at wounds in zebrafish

    by Caroline Coombs, Antonios Georgantzoglou, Hazel A. Walker, Julian Patt, Nicole Merten, Hugo Poplimont, Elisabeth M. Busch-Nentwich, Sarah Williams, Christina Kotsi, Evi Kostenis, et al.

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.


  • Open Access

    Chemokine receptor trafficking coordinates neutrophil clustering and dispersal at wounds in zebrafish

    by Caroline Coombs, Antonios Georgantzoglou, Hazel A. Walker, Julian Patt, Nicole Merten, Hugo Poplimont, Elisabeth M. Busch-Nentwich, Sarah Williams, Christina Kotsi, Evi Kostenis, et al.

    Immune cells congregate at specific loci to fight infections during inflammatory responses, a process that must be transient and self-resolving. Cell dispersal promotes resolution, but it remains unclear how transition from clustering to dispersal is regulated. Here we show, using quantitative live imaging in zebrafish, that differential ligand-induced trafficking of chemokine receptors such as Cxcr1 and Cxcr2 orchestrates the state of neutrophil congregation at sites of tissue damage. Through receptor mutagenesis and biosensors, we show that Cxcr1 promotes clustering at wound sites, but is promptly desensitized and internalized, which prevents excess congregation. By contrast, Cxcr2 promotes bidirectional motility and is sustained at the plasma membrane. Persistent plasma membrane residence of Cxcr2 prolongs downstream signaling and is required for sustained exploratory motion conducive to dispersal. Thus, differential trafficking of two chemokine receptors allows coordination of antagonistic cell behaviors, promoting a self-resolving migratory response.